Literature DB >> 25355460

Strategies to maximize liposomal drug loading for a poorly water-soluble anticancer drug.

Wenli Zhang1, Guangji Wang, James R Falconer, Bruce C Baguley, John P Shaw, Jianping Liu, Hongtao Xu, Esther See, Jianguo Sun, Jiye Aa, Zimei Wu.   

Abstract

PURPOSE: To develop a liposomal system with high drug loading (DL) for intravenous (i.v.) delivery of a poorly water-soluble basic drug, asulacrine (ASL).
METHODS: A thin-film hydration and extrusion method was used to fabricate the PEGylated liposomal membranes followed by a freeze and thaw process. A novel active drug loading method was developed using ammonium sulphate gradient as an influx driving force of ASL solubilized with sulfobutyl ether-β-cyclodextrin (SBE-β-CD). DL was maximized by optimizing liposomal preparation and loading conditions. Pharmacokinetics was evaluated following i.v. infusion in rabbits.
RESULTS: Freeze-thaw resulted in unilamellar liposome formation (180 nm) free of micelles. Higher DL was obtained when dialysis was used to remove the untrapped ammonium sulphate compared to ultracentrifuge. The pH and SBE-β-CD level in the loading solution played key roles in enhancing DL. High DL ASL-liposomes (8.9%w/w, drug-to-lipid mole ratio 26%) were obtained with some drug "bundles" in the liposomal cores and were stable in a 5% glucose solution for >80 days with minimal leakage (<2%). Surprisingly, following administration of ASL-liposomes prepared with or without SBE-β-CD, the half-lives were similar to the drug solution despite an increased area under the curve, indicating drug leakage from the carriers.
CONCLUSIONS: High liposomal DL was achieved with multiple strategies for a poorly-water soluble weak base. However, the liposomal permeability needed to be tailored to improve drug retention.

Entities:  

Mesh:

Substances:

Year:  2014        PMID: 25355460     DOI: 10.1007/s11095-014-1551-8

Source DB:  PubMed          Journal:  Pharm Res        ISSN: 0724-8741            Impact factor:   4.200


  37 in total

1.  Enhanced active liposomal loading of a poorly soluble ionizable drug using supersaturated drug solutions.

Authors:  Sweta Modi; Tian-Xiang Xiang; Bradley D Anderson
Journal:  J Control Release       Date:  2012-07-16       Impact factor: 9.776

2.  Loading of amphipathic weak acids into liposomes in response to transmembrane calcium acetate gradients.

Authors:  S Clerc; Y Barenholz
Journal:  Biochim Biophys Acta       Date:  1995-12-13

3.  The encapsulation of idarubicin within liposomes using the novel EDTA ion gradient method ensures improved drug retention in vitro and in vivo.

Authors:  Jerzy Gubernator; Grzegorz Chwastek; Mariola Korycińska; Maria Stasiuk; Grzegorz Grynkiewicz; Felicitas Lewrick; Regine Süss; Arkadiusz Kozubek
Journal:  J Control Release       Date:  2010-05-24       Impact factor: 9.776

4.  Study of the relationship between lipid binding properties of cyclodextrins and their effect on the integrity of liposomes.

Authors:  G Piel; M Piette; V Barillaro; D Castagne; B Evrard; L Delattre
Journal:  Int J Pharm       Date:  2007-01-19       Impact factor: 5.875

5.  Curcumin-derivative nanomicelles for the treatment of triple negative breast cancer.

Authors:  Sebastien Taurin; Hayley Nehoff; Jasper Diong; Lesley Larsen; Rhonda J Rosengren; Khaled Greish
Journal:  J Drug Target       Date:  2013-05-16       Impact factor: 5.121

6.  Synthesis, antitumor activity, and DNA binding properties of a new derivative of amsacrine, N-5-dimethyl-9-[(2-methoxy-4-methylsulfonylamino) phenylamino]-4-acridinecarboxamide.

Authors:  B C Baguley; W A Denny; G J Atwell; G J Finlay; G W Rewcastle; S J Twigden; W R Wilson
Journal:  Cancer Res       Date:  1984-08       Impact factor: 12.701

7.  Disposition of bisantrene in humans and rabbits: evidence for intravascular deposition of drug as a cause of phlebitis.

Authors:  G Powis; J S Kovach
Journal:  Cancer Res       Date:  1983-02       Impact factor: 12.701

8.  Cell line selectivity and DNA breakage properties of the antitumour agent N-[2-(dimethylamino)ethyl]acridine-4-carboxamide: role of DNA topoisomerase II.

Authors:  E Schneider; S J Darkin; P A Lawson; L M Ching; R K Ralph; B C Baguley
Journal:  Eur J Cancer Clin Oncol       Date:  1988-11

Review 9.  Nanocarriers as an emerging platform for cancer therapy.

Authors:  Dan Peer; Jeffrey M Karp; Seungpyo Hong; Omid C Farokhzad; Rimona Margalit; Robert Langer
Journal:  Nat Nanotechnol       Date:  2007-12       Impact factor: 39.213

10.  Transmembrane gradient driven phase transitions within vesicles: lessons for drug delivery.

Authors:  D D Lasic; B Ceh; M C Stuart; L Guo; P M Frederik; Y Barenholz
Journal:  Biochim Biophys Acta       Date:  1995-11-01
View more
  11 in total

1.  Optimization of Weight Ratio for DSPE-PEG/TPGS Hybrid Micelles to Improve Drug Retention and Tumor Penetration.

Authors:  Ya Jin; Zimei Wu; Caibin Li; Weisai Zhou; John P Shaw; Bruce C Baguley; Jianping Liu; Wenli Zhang
Journal:  Pharm Res       Date:  2018-01-04       Impact factor: 4.200

2.  Development of Long-Circulating pH-Sensitive Liposomes to Circumvent Gemcitabine Resistance in Pancreatic Cancer Cells.

Authors:  Hongtao Xu; James W Paxton; Zimei Wu
Journal:  Pharm Res       Date:  2016-03-10       Impact factor: 4.200

3.  Mixed Liposome Approach for Ratiometric and Sequential Delivery of Paclitaxel and Gemcitabine.

Authors:  Yuanfen Liu; Hassan Tamam; Yoon Yeo
Journal:  AAPS PharmSciTech       Date:  2017-10-02       Impact factor: 3.246

Review 4.  High drug-loading nanomedicines: progress, current status, and prospects.

Authors:  Shihong Shen; Youshen Wu; Yongchun Liu; Daocheng Wu
Journal:  Int J Nanomedicine       Date:  2017-05-31

5.  Cyclic-RGDyC functionalized liposomes for dual-targeting of tumor vasculature and cancer cells in glioblastoma: An in vitro boron neutron capture therapy study.

Authors:  Weirong Kang; Darren Svirskis; Vijayalekshmi Sarojini; Ailsa L McGregor; Joseph Bevitt; Zimei Wu
Journal:  Oncotarget       Date:  2017-05-30

6.  Multiseed liposomal drug delivery system using micelle gradient as driving force to improve amphiphilic drug retention and its anti-tumor efficacy.

Authors:  Wenli Zhang; Caibin Li; Ya Jin; Xinyue Liu; Zhiyu Wang; John P Shaw; Bruce C Baguley; Zimei Wu; Jianping Liu
Journal:  Drug Deliv       Date:  2018-11       Impact factor: 6.419

7.  Development of Drug Dual-Carriers Delivery System with Mitochondria-Targeted and pH/Heat Responsive Capacity for Synergistic Photothermal-Chemotherapy of Ovarian Cancer.

Authors:  Xiaoxia Guo; Jie Mei; Chunping Zhang
Journal:  Int J Nanomedicine       Date:  2020-01-16

8.  Aptamer-functionalized peptide H3CR5C as a novel nanovehicle for codelivery of fasudil and miRNA-195 targeting hepatocellular carcinoma.

Authors:  Ying Liu; Xin Wu; Yuan Gao; Jigang Zhang; Dandan Zhang; Shengying Gu; Guanhua Zhu; Gaolin Liu; Xiaoyu Li
Journal:  Int J Nanomedicine       Date:  2016-08-12

9.  Optimization of Docetaxel Loading Conditions in Liposomes: proposing potential products for metastatic breast carcinoma chemotherapy.

Authors:  Roghayyeh Vakili-Ghartavol; Seyed Mahdi Rezayat; Reza Faridi-Majidi; Kayvan Sadri; Mahmoud Reza Jaafari
Journal:  Sci Rep       Date:  2020-03-27       Impact factor: 4.379

Review 10.  Liposomes to Augment Dialysis in Preclinical Models: A Structured Review.

Authors:  Kevin Hart; Martyn Harvey; Mingtan Tang; Zimei Wu; Grant Cave
Journal:  Pharmaceutics       Date:  2021-03-16       Impact factor: 6.321

View more

北京卡尤迪生物科技股份有限公司 © 2022-2023.